Complex interactions between the microbiome and cancer immune therapy.

Area of Science:

• Oncology
• Immunology
• Microbiome Research

Background:

• Immuno-oncology, particularly immune checkpoint inhibitors (ICIs), has advanced cancer treatment.
• Predictive biomarkers for ICI efficacy and toxicity remain limited.
• The gut microbiome is emerging as a key factor influencing cancer immunotherapy.

Purpose of the Study:

• To review methods for microbiome analysis in cancer research.
• To summarize findings on the microbiome's role in ICI response and toxicity.
• To discuss microbiome modulation strategies for cancer therapy.

Main Methods:

• Review of studies using 16S rRNA and shotgun metagenomic sequencing.
• Analysis of pre-clinical and clinical data on microbiome composition and ICI outcomes.
• Examination of therapeutic interventions like probiotics and fecal microbiota transplant (FMT).

Main Results:

• Microbiome composition correlates with ICI efficacy and the development of colitis.
• Specific bacterial taxa may enhance anti-cancer effects but also increase colitis risk.
• Probiotics and FMT show potential in managing ICI-induced colitis.

Conclusions:

• The gut microbiome is a critical determinant of cancer immunotherapy success and safety.
• Targeting the microbiome offers a promising avenue for improving patient outcomes.
• Future research may leverage advanced microbial therapies for cancer treatment and side effect management.